Crossmark

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

Crossref DOI link: https://doi.org/10.1007/s13300-020-00980-1

Published Online: 2020-12-11

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jendle, Johan https://orcid.org/0000-0003-1025-1682
Ericsson, Åsa

Gundgaard, Jens

Møller, Jonas Bech

Valentine, William J.

Hunt, Barnaby
Funding

Funding for this research was provided by:

Novo Nordisk A/S
License Information

Text and Data Mining valid from 2020-12-11

Version of Record valid from 2020-12-11
More Information

Article History

Received: 12 October 2020

Accepted: 28 November 2020

First Online: 11 December 2020

Document is current

Any future updates will be listed below